Navigation Links
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
Date:4/17/2008

ommercially-available gabapentin.

Absorption of commercially-available gabapentin is limited to a narrow region in the intestinal tract and can saturate at normal clinical doses. Once saturation occurs, additional gabapentin can not be absorbed. In addition, absorption rates can vary from patient to patient. In contrast, studies with both the immediate-release and the sustained-release formulations indicated that XP13512 was well-absorbed, converted rapidly to gabapentin and provided high bioavailability (>70 percent) and dose-proportional exposure.

"XP13512 is absorbed by high-capacity nutrient transporters located throughout the intestinal tract," said Ken Cundy, Ph.D., senior vice president, Preclinical Development for XenoPort. "The unique absorption mechanism of this compound overcomes the pharmacokinetic limitations of commercially-available gabapentin and allows for sustained, dose-proportional exposure to gabapentin."

About PIVOT RLS I (Study XP052)

PIVOT RLS I, a 12-week, multicenter, randomized, double-blind, placebo- controlled clinical trial of XP13512 was designed to assess efficacy and tolerability in adults with moderate-to-severe primary RLS. The study included 220 patients randomized to receive either XP13512 1200 mg (n=112) or placebo (n=108) once-daily at 5:00 p.m. with food. Co-primary endpoints in the study were mean change from baseline in the International Restless Legs Syndrome (IRLS) Scale total score and the proportion of responders (defined as ratings of 'very much improved' or 'much improved') on the investigator-rated Clinical Global Impression of Improvement (CGI-I) Scale at Week 12. Adverse events, vital signs and laboratory tests were used to assess tolerability.

Study results showed that the unadjusted mean change from baseline in IRLS Scale total score at Week 12 was significantly greater for XP13512 (-13.2) compared to placebo (-8.8) with an adjusted mean treatment difference of -4.0, 95% CI: (-6.
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education Professional, ... the science, technical, and medical communities, has announced the ... off-line mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all ... be able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... New York , July 29, 2014 ... by Transparency Market Research "Orthopedic Trauma Fixation Devices Market ... Analysis 2014 - 2020", the global orthopedic trauma fixation ... 2014 and is expected to grow at a CAGR ... estimated value of USD 9.3 billion in 2020. ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today ... a new corporate logo. This is part of a comprehensive ... Founded in Boston, MA , in ... of companies since 1992.  Other companies in the group include ... and Systelab ( Barcelona, Spain ).  Like IL, ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
... BERWYN, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Encorium Group, ... multinational clinical research organization (CRO) conducting studies in over ... and biotechnology companies, today announced that it has appointed ... 7, 2009. Ms. Laitinen, age 43, will replace ...
Cached Medicine Technology:Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 2Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily ... that the program was actually created by a popular ... too. He tried numerous treatments for this disorder, but ... found himself in the situation of having to look ... years of research. Dawson used this method, too, to ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... Angeles, CA (PRWEB) July 29, 2014 ... the website of Time Magazine titled “From Kim’s Butt ... Kim Kardashian’s butt is the celebrity feature ... and their features include Beyoncé’s butt, Jennifer Lawrence’s ... lips. This information is based on data collected by ...
(Date:7/29/2014)... 29, 2014 Tylenol lawsuits ( ... allegedly suffered serious liver injuries due to the ... in a multidistrict litigation underway in U.S. District ... reports. According to an Order dated July 23rd, ... to bellwether case and discovery issues. Among other ...
(Date:7/29/2014)... Avenidas is always looking for ... again, the non-profit agency is doing just that with the ... , This event gives seniors the opportunity to learn about ... will be a variety of fun activities, including a Tai ... and artists. In addition, there will be food tastings, courtesy ...
Breaking Medicine News(10 mins):Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2
... Total hip arthroplasty (THA), or hip replacement, is ... studies have only followed patients for up to ... December issue of Arthritis Care & Research ( ... eight years following hip replacement and found a ...
... obtained agreement with the United States, Food and Drug ... SP1049C for the treatment of metastatic adenocarcinoma of the ... upper gastrointestinal tract, ... clinical trial will compare SP1049C plus Best Supportive Care (BSC),versus BSC ...
... Flick, presents World AIDS Day Special ... SIRIUS Satellite Radio,Interview with Madonna and exclusive performances from Cyndi Lauper, Indigo ... Bell and others, NEW YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: ... --,Saturday, December 1 -- with an exclusive broadcast event on SIRIUS OutQ,109, ...
... Over the past few weeks,there has been a ... the meat industry and the USDA that permits ... failed to be "non-negative" for E.,coli O157:H7,( http://www.ehagroup.com/epidemiology/illnesses/e-coli-O157-H7.asp ... includes cooking to the thermal death,stage for all ...
... Breast cancer is a disease with a number ... have seen that these risks are often compounded by ... exactly, do social disadvantages, genetics, race and culture add ... women? , These are among the questions in ...
... of Americans still weigh much too much, study finds , , ... hasn,t increased much in recent years, but there are still ... study reports. , The study, based on 2005-06 data from ... , More than a third of American adults (about 72 ...
Cached Medicine News:Health News:Long-term improvement seen with hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 2Health News:The USDA 'E. coli Loophole' in Ground Beef: Much Ado About Nothing 3Health News:New perspectives on health disparities in breast cancer research 2Health News:New perspectives on health disparities in breast cancer research 3Health News:New perspectives on health disparities in breast cancer research 4Health News:New perspectives on health disparities in breast cancer research 5Health News:New perspectives on health disparities in breast cancer research 6Health News:New perspectives on health disparities in breast cancer research 7Health News:New perspectives on health disparities in breast cancer research 8Health News:Obesity Rates Leveling Off Among U.S. Adults 2
... Philadelphia™ Collar and Stabilizer Plastazote® ... reinforcements. Hook-and-pile closure straps. Chin ... mandibular pieces may be interchanged ... easily to the standard Philadelphia ...
Urethrotome - non-optical...
Optical Urethrotome for Telescope 2.7 mm for children....
... The USA Elite ... Visual Urethrotomes are utilized ... strictures and bladder neck ... The visual obturator converts ...
Medicine Products: